You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

CLINICAL TRIALS PROFILE FOR FIDAXOMICIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Fidaxomicin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00314951 ↗ Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018) Completed Optimer Pharmaceuticals LLC Phase 3 2006-05-02 This is a comparative study to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD).
NCT00468728 ↗ PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Completed Optimer Pharmaceuticals LLC Phase 3 2006-10-04 This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).
NCT01552668 ↗ Fidaxomicin to Prevent Clostridium Difficile Colonization Withdrawn Centers for Disease Control and Prevention Phase 4 2012-09-01 The purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing C. difficile infection.
NCT01552668 ↗ Fidaxomicin to Prevent Clostridium Difficile Colonization Withdrawn Washington University School of Medicine Phase 4 2012-09-01 The purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing C. difficile infection.
NCT01591863 ↗ Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) Completed Optimer Pharmaceuticals LLC Phase 2 2012-06-15 The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of fidaxomicin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD).
NCT01691248 ↗ Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) Completed Optimer Pharmaceuticals LLC Phase 3 2012-10-10 The objective of this study is to demonstrate the efficacy and safety of Fidaxomicin versus placebo for prophylaxis against Clostridium difficile-Associated Diarrhea (CDAD) in adult participants undergoing hematopoietic stem cell transplantation (HSCT). The primary hypothesis is that Fidaxomicin is superior to placebo in preventing CDAD in participants undergoing HSCT.
NCT01775397 ↗ A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System Terminated Cubist Pharmaceuticals LLC Phase 4 2012-11-29 The primary objective is to compare fidaxomicin versus vancomycin for the sustained clinical cure of Clostridium difficile Infection (CDI) in adult patients receiving immunosuppressive therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fidaxomicin

Condition Name

Condition Name for Fidaxomicin
Intervention Trials
Clostridium Difficile Infection 10
Clostridium Difficile 6
Diarrhea 4
Clostridium Difficile Infection (CDI) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fidaxomicin
Intervention Trials
Clostridium Infections 31
Infections 20
Communicable Diseases 15
Infection 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fidaxomicin

Trials by Country

Trials by Country for Fidaxomicin
Location Trials
United States 133
Canada 17
United Kingdom 8
Poland 7
France 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fidaxomicin
Location Trials
California 8
New York 7
Texas 6
North Carolina 6
Massachusetts 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fidaxomicin

Clinical Trial Phase

Clinical Trial Phase for Fidaxomicin
Clinical Trial Phase Trials
Phase 4 13
Phase 3 11
Phase 2 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fidaxomicin
Clinical Trial Phase Trials
Completed 17
Recruiting 7
Terminated 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fidaxomicin

Sponsor Name

Sponsor Name for Fidaxomicin
Sponsor Trials
Optimer Pharmaceuticals LLC 5
Merck Sharp & Dohme Corp. 4
Cubist Pharmaceuticals LLC 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fidaxomicin
Sponsor Trials
Other 36
Industry 26
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Fidaxomicin: Clinical Trials, Market Analysis, and Projections

Introduction to Fidaxomicin

Fidaxomicin is a narrow-spectrum antibiotic specifically designed to treat Clostridioides difficile infections (CDI), a common cause of hospital-acquired diarrhea. Here, we delve into the recent clinical trials, market analysis, and future projections for this drug.

Clinical Trials Update

Adult Studies

Several clinical trials have compared fidaxomicin with vancomycin, the standard treatment for CDI. A phase 3 study involving two global, randomized, double-blind trials (Ri-CoDIFy 1 and 2) demonstrated that fidaxomicin had lower recurrence rates compared to vancomycin. The study, conducted at 157 sites in 26 countries, showed that fidaxomicin achieved higher global cure rates and reduced the risk of recurrent CDI[1].

Pediatric Studies

In pediatric patients, fidaxomicin has also shown promising results. A multicenter, investigator-blind, phase 3 trial (SUNSHINE) compared fidaxomicin with vancomycin in children and adolescents with CDI. The study found that fidaxomicin was well tolerated and resulted in significantly higher global cure rates (68.4% vs 50.0%) compared to vancomycin[3].

Efficacy and Safety

Clinical Response and Recurrence

Fidaxomicin has consistently demonstrated higher global cure rates and lower recurrence rates of CDI compared to vancomycin. A meta-analysis pooling data from several RCTs showed that fidaxomicin was associated with a reduced risk of recurrent CDI (RR 0.59, 95% CI 0.47-0.75) and improved global cure rates (RR 1.18, 95% CI 1.09-1.26)[4].

Safety Profile

Fidaxomicin has been shown to be well tolerated in both adult and pediatric populations. The drug has minimal systemic absorption and high stool concentrations, which helps in maintaining the normal gut flora, thereby reducing the risk of further infections[3][4].

Market Analysis

Market Size and Growth

The global fidaxomicin market has been growing steadily. In 2021, the market size was USD 532.08 million and is expected to reach USD 721.63 million by 2027, exhibiting a Compound Annual Growth Rate (CAGR) of 5.21%. By 2032, the market is projected to reach USD 930.25 million[5].

Market Drivers

Several factors are driving the growth of the fidaxomicin market:

  • Increasing Geriatric Population: The elderly are more susceptible to infections, including CDI, which increases the demand for effective treatments like fidaxomicin[5].
  • Rising Healthcare Expenditures: Growing healthcare expenditures in developing nations create opportunities for the expansion of the fidaxomicin market[2].
  • Expansion of Healthcare Infrastructure: The development of healthcare infrastructure in emerging economies further drives the market forward[2].

Market Restraints

Despite the growth potential, the fidaxomicin market faces several challenges:

  • High Production and R&D Costs: These costs limit the affordability and accessibility of fidaxomicin, particularly in low-income regions[2].
  • Regulatory Hurdles: Stringent regulatory approval processes can impede the global dissemination of fidaxomicin treatments[2].
  • Competition from Alternative Therapies: The market is competitive, with other antibiotics and treatments vying for market share[2].

Market Opportunities

Emerging Markets

There are significant opportunities for fidaxomicin in developing economies, where healthcare infrastructure is expanding. Increasing awareness and education among medical practitioners about the efficacy of fidaxomicin can further drive market growth[2].

Technological Advancements

Advancements in pharmaceutical technology can improve the efficacy and sustainability of fidaxomicin. Developing novel delivery mechanisms and exploring combination therapies could broaden the application spectrum of fidaxomicin[2].

Growing Demand in Healthcare Facilities

The increasing focus on infection control measures in healthcare facilities is driving the demand for effective treatments like fidaxomicin[2].

Porter’s Five Forces Analysis

Competitive Rivalry

The fidaxomicin market is characterized by moderate to high competitive rivalry due to the presence of other antibiotics and treatments. Companies must understand their competitive position and adapt strategies to maintain market share[2].

Threat of New Entrants

The threat of new entrants is moderate due to high development and production costs, as well as stringent regulatory requirements. However, new products or companies could potentially disrupt the market[2].

Bargaining Power of Buyers

The bargaining power of buyers is relatively high, especially in healthcare settings where cost-effectiveness is a significant factor. Buyers may prefer cheaper alternatives, which can impact fidaxomicin's market share[2].

Bargaining Power of Suppliers

The bargaining power of suppliers is moderate. While there are limited suppliers for certain components, the overall supply chain is relatively stable, though it can be affected by disruptions[2].

Threat of Substitute Products

The threat of substitute products is high due to the availability of other antibiotics and treatments for CDI. Fidaxomicin must compete with these alternatives to maintain its market position[2].

Key Takeaways

  • Fidaxomicin has shown superior efficacy and safety in treating CDI compared to vancomycin in both adult and pediatric populations.
  • The global fidaxomicin market is expected to grow significantly, driven by increasing healthcare expenditures and the expansion of healthcare infrastructure.
  • High production and R&D costs, regulatory hurdles, and competition from alternative therapies are key challenges.
  • Emerging markets and technological advancements offer significant opportunities for growth.

FAQs

What is the expected growth rate of the fidaxomicin market from 2024 to 2032?

The fidaxomicin market is expected to exhibit a CAGR of 5.21% from 2024 to 2032[5].

Which companies are major players in the fidaxomicin market?

Astellas Pharma, Merck, and Biocon are some of the top companies operating in the fidaxomicin market[5].

What are the primary drivers of the fidaxomicin market?

The primary drivers include the growing geriatric population, rising healthcare expenditures, and the expansion of healthcare infrastructure in emerging economies[2][5].

What are the main challenges facing the fidaxomicin market?

High production and R&D costs, regulatory hurdles, and competition from alternative therapies are significant challenges[2].

How does fidaxomicin compare to vancomycin in treating CDI?

Fidaxomicin has been shown to have higher global cure rates and lower recurrence rates of CDI compared to vancomycin in clinical trials[1][3][4].

Sources

  1. Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection. Clinical Infectious Diseases, 2024.
  2. Fidaxomicin Drugs Market Size & Share 2025-2030. 360 Research Reports.
  3. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides difficile Infection. Clinical Infectious Diseases, 2023.
  4. Fidaxomicin for the Treatment of Clostridioides difficile Infection in Adults and Children: A Narrative Review. MDPI, 2022.
  5. Fidaxomicin Market Size - Forecast To 2032. Business Research Insights.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.